Abstract
Adalimumab joins free existing biologic agents for the treatment of RA. Its place among these therapeutic options is unclear until head-to-head studies are performed with adalimumab and other biologic DMARDs. Adalimumab is currently in clinical trials for additional therapeutic uses, namely Crohn's disease and coronary artery disease.
MeSH terms
-
Adalimumab
-
Antibodies, Monoclonal / economics
-
Antibodies, Monoclonal / metabolism
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / economics
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Clinical Trials as Topic
-
Drug Therapy, Combination
-
Humans
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Tumor Necrosis Factor-alpha
-
Adalimumab